Inhibrx Biosciences has 7 investors with a majority stake of 50%. Institutions hold 43% ownership, facing the biggest gain or loss. Hedge funds and individuals also hold significant stakes, with Viking Global Investors LP as the largest shareholder. CEO Mark Lappe owns 6.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing